Landmark Global Population Study Begins to Unlock Genetic History of Human Migration FOSTER CITY, Calif.–As some early humans began to leave their native Africa around 60,000 years ago in a wave of migration that would ultimately populate the planet, they began to slowly accumulate and pass down various random genetic mutations that would ultimately result in the diversity we see in people today. Analyzing these genetic variations in order to better understand human diversity and the history of thousands of years of global migration is the goal of the Genographic Project – a five-year research partnership between National Geographic and IBM, with field support from the Waitt Family Foundation, and DNA analysis technology from Applied Biosystems (NYSE:ABI – News), an Applera Corporation business. Applied Biosystems, a leading global supplier of life-sciences technology, joined the Genographic Project (www.nationalgeographic.com/genographic) as a supporting sponsor in 2006. Each of the 10 participating global research centers use AB equipment and services in their laboratories. Since joining the Project, the company has been equipping the regional laboratories with a complete workflow for advanced genetic analysis consisting of instruments, reagents, and software, as well as providing training and support, including designing a custom set of genetic assays for the project. The Genographic Researchers utilize Applied Biosystems technology for their ongoing genetic analysis of the field samples. One of a series of planned publications from this field research appeared last month in the American Journal of Human Genetics from the Lebanese American University in Beirut.1 The scientific team for this paper was led by Pierre Zalloua, Ph.D. and Chris Tyler-Smith, Ph.D. They used a combination of the company’s genotyping technologies to show that both the Islamic Expansion from the Arabian Peninsula beginning in the 7th Century and the Crusades originating out of Western Europe in the 11th-13th centuries, left a genetic footprint on the modern-day Lebanese population. The Genographic Team conducted two types of genotyping analysis to identify the historical markers. Their approach involved studying the non-recombinant region of the Y-chromosome, which does not change with each generation, but is directly passed down from father to son. Rare and random mutations provide the only changes to this area of the chromosome. As a result, scientists can look at polymorphisms resulting from these small and infrequent changes to identify how migrating populations intermixed and left recognizable genetic markers in modern populations in different parts of the world. For the first type of analysis, the team used the Applied Biosystems 7900HT Real-Time PCR System and a set of Custom TaqMan® Genotyping Assays to assign each of the 926 samples to a haplogroup, which is determined by a common variation that broadly defines the branch of the ancestral tree to which an individual belongs. After showing that both Western European and Arabian markers appeared in the modern-day Lebanese population, the team used a second technological approach to investigate whether these findings could be confirmed and more specific origins suggested. For the second analysis, the team used the Applied Biosystems 3130xl Genetic Analyzer with the AmpFℓSTR® Yfiler® PCR Amplification Kit and a set of custom Y-STR primers to assign each sample to a specific haplotype. This process further refines a person’s ancestry by revealing a detailed lineage that can be family-specific. The result of this analysis suggested that some of the lineages found in the modern-day Lebanese population were in fact the result of historical migrations from Western Europe during the Crusades. “We found a striking correlation between documented historic events and the genetic signatures identified in the current population of Lebanese men,” said Dr. Zalloua. “Applied Biosystems’ lab technologies were chosen and used for this project both for their unprecedented reliability and the tremendous scientific expertise the company brings to our research. I believe the latest study is just the tip of the iceberg of what we can do with the Applied Biosystems technology.” The other laboratories participating in the project are located at: the University of Pennsylvania in Philadelphia (USA), Institut Pasteur (France), Universitat Pompeu Fabra (Spain), Russian Academy of Medical Sciences (Russia), La Trobe University (Australia), Fudan University (China), Madurai Kamaraj University (India), National Health Laboratory Service (South Africa), and the Australian Centre for Ancient DNA at the University of Adelaide (Australia), and the Universidade Federal de Minas Gerais (Brazil). In addition to the previously mentioned Applied Biosystems technologies, the laboratories are also using the GeneAmp® PCR System 9700 and custom primers for mitochondrial sequencing for analysis of maternal lineages on the 3130xl Genetic Analyzer. The 3130xl is a 16-capillary electrophoresis instrument based on Applied Biosystems’ gold-standard Sanger sequencing technology. The company also provides two software packages to support the capture and analysis of the results of the genotyping and sequencing analyses – the GeneMapper ID® Software and the Variant Reporter™ Software. These software packages convert the results into a standard file format to support efficient file sharing among the participating laboratories and for storage in the central database. Janet Ziegle, a senior staff scientist at Applied Biosystems, has been working with Genographic Project principal investigators to provide technical support, and leads the design of custom assays for the project. “Every year, advances in DNA analysis technologies are having an enormous impact on society, and this project has the potential to rewrite textbooks,” said Ziegle. “The Genographic Project serves as a model for other types of research that can benefit from advances in DNA analysis to unlock history.” The Genographic Project is a ground-breaking research partnership of the National Geographic Society and IBM to map the history of human migration, with global field science supported by the Waitt Family Foundation. Applied Biosystems is a leading global provider of life science technologies. The company brings a more than 25-year history of groundbreaking life science innovation to the project, including the development of the technologies that enabled the historic sequencing of the human genome. For more information about the project, visit www.nationalgeographic.com/genographic. For more information about Applied Biosystems, visit www.appliedbiosystems.com. About Applera Corporation and Applied Biosystems Applera Corporation consists of two operating groups. Applied Biosystems serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems’ products also serve the needs of some markets outside of life science research, which we refer to as “applied markets,” such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, such as testing required for food and pharmaceutical manufacturing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of approximately $2.1 billion during fiscal 2007. The Celera Group is a diagnostics business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and optimize patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information unless required by law.